
    
      Up to 275 study eyes with progressive keratoconus will be enrolled. Study eyes will be
      randomized in a 2:1 ratio to receive CXL treatment or sham/control treatment.The primary
      efficacy endpoint is a difference of â‰¥ 1 diopter between treatment groups in the mean change
      in Kmax from baseline to Month 6.
    
  